Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm

[1]  Bettina Wabbels,et al.  Difficulties with differentiating botulinum toxin treatment effects in essential blepharospasm , 2011, Journal of Neural Transmission.

[2]  J. Frevert.  Content of Botulinum Neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture® , 2010, Drugs in R&D.

[3]  T. Hunt,et al.  Editorial Response Letter to Mander et al , 2009 .

[4]  J. Jankovic,et al.  Relationship between various clinical outcome assessments in patients with blepharospasm , 2009, Movement disorders : official journal of the Movement Disorder Society.

[5]  V. Kostic,et al.  Quality of life in patients with focal dystonia , 2009, Clinical Neurology and Neurosurgery.

[6]  T. Hunt,et al.  Potency Evaluation of a Formulated Drug Product Containing 150-kd Botulinum Neurotoxin Type A , 2008, Clinical neuropharmacology.

[7]  A. Brashear.  Clinical Comparisons of Botulinum Neurotoxin Formulations , 2008, The neurologist.

[8]  Gerd J. Mander,et al.  Equivalent potency of Xeomin® and BOTOX® , 2008 .

[9]  W. Jost,et al.  Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm , 2006, Journal of Neural Transmission.

[10]  E. Růžička,et al.  A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia , 2005, Neurology.

[11]  W. Jost,et al.  Botulinum toxin: evidence-based medicine criteria in blepharospasm and hemifacial spasm , 2001, Journal of Neurology.

[12]  E. Cassetta,et al.  A prevalence study of primary dystonia in eight European countries , 2000, Journal of Neurology.

[13]  M. Hallett,et al.  Blepharospasm , 1996, Neurology.

[14]  J Jankovic,et al.  Botulinum A toxin for cranial‐cervical dystonia , 1987, Neurology.

[15]  A. B. Scott,et al.  Botulinum A toxin injection as a treatment for blepharospasm. , 1985, Archives of ophthalmology.

[16]  L. Simpson.  The origin, structure, and pharmacological activity of botulinum toxin. , 1981, Pharmacological reviews.

[17]  L. Kline,et al.  Health-related quality of life and psychosocial characteristics of patients with benign essential blepharospasm. , 2006, Archives of ophthalmology.

[18]  T. Warner.  The Epidemiological Study of Dystonia in Europe (ESDE) Collaborative Group A prevalence study of primary dystonia in eight European countries , 2000 .